1|Page
NURS 615 PHARM EXAM 1 – MARYVILLE
UPDATED QUESTIONS AND CORRECT
ANSWERS 100% VERIFIED|| LATEST AND
COMPLETE UPDATE 2025-2026 WITH
EXPERT SOLUTIONS|| ASSURED PASS!!
1. How does hypoalbuminemia affect the process of prescribing?
- ANSWER: Low albumin
= more free drug (bc the drug can't bind to albumin aka protein) = increased
adverse effects
2. What is a Black Box Warning
- ANSWER: is considered a contraindication to administer that drug.
3. What is the drugs half-life?
- ANSWER: Half-life specifically means the amount of time it takes for an
administered drug to be halfway cleared from the system.
4. Peak of action
- ANSWER: the time between drug administration and maximum concentra- tion
of drug in the blood stream. Best therapeutic effect.
5. Duration of action
,2|Page
- ANSWER: the time between onset of action and metabolism of drug below the
minimum needed for an effect. The length of time you have the drug in your
system.
6. According to the WHO what is the first step in the prescribing process?
- ANSWER: The first step is to define the patient's problem
7. The second step is to
- ANSWER: specify the therapeutic objective
8. The third step is to
- ANSWER: choose which drug or treatment is needed.
9. Step 4 of the WHO approach
- ANSWER: Start the treatment
10. Step 5 of the WHO approach
- ANSWER: Educate the patient
11. Step 6 of the WHO approach
- ANSWER: Monitor the treatment
, 3|Page
12. Phase 1 of drug development
- ANSWER: The drug is tested on healthy volunteers
13. Phase 2 of drug development
- ANSWER: trials with people who have the disease for which the drug is
thought to be effective
14. Phase 3 of drug development
- ANSWER: Large numbers of patients in medical research centers receive the
drug in phase 3. This larger sampling provides information about infrequent or rare
adverse effects. The FFA will approve a new drug application if phase 3 studies are
satisfactory.
15. Phase 4 of drug development
- ANSWER: This phase is voluntary and involves post- market surveillance of
the drug's therapeutic effects at the completion of phase 3. The pharmaceutical
company receives reports from doctors and other health care professionals about
the therapeutic results and adverse effects of the drug. Some medications, for
example, have been found to be toxic and have been removed from the market
after their initial release.
16. Explain first pass metabolism
NURS 615 PHARM EXAM 1 – MARYVILLE
UPDATED QUESTIONS AND CORRECT
ANSWERS 100% VERIFIED|| LATEST AND
COMPLETE UPDATE 2025-2026 WITH
EXPERT SOLUTIONS|| ASSURED PASS!!
1. How does hypoalbuminemia affect the process of prescribing?
- ANSWER: Low albumin
= more free drug (bc the drug can't bind to albumin aka protein) = increased
adverse effects
2. What is a Black Box Warning
- ANSWER: is considered a contraindication to administer that drug.
3. What is the drugs half-life?
- ANSWER: Half-life specifically means the amount of time it takes for an
administered drug to be halfway cleared from the system.
4. Peak of action
- ANSWER: the time between drug administration and maximum concentra- tion
of drug in the blood stream. Best therapeutic effect.
5. Duration of action
,2|Page
- ANSWER: the time between onset of action and metabolism of drug below the
minimum needed for an effect. The length of time you have the drug in your
system.
6. According to the WHO what is the first step in the prescribing process?
- ANSWER: The first step is to define the patient's problem
7. The second step is to
- ANSWER: specify the therapeutic objective
8. The third step is to
- ANSWER: choose which drug or treatment is needed.
9. Step 4 of the WHO approach
- ANSWER: Start the treatment
10. Step 5 of the WHO approach
- ANSWER: Educate the patient
11. Step 6 of the WHO approach
- ANSWER: Monitor the treatment
, 3|Page
12. Phase 1 of drug development
- ANSWER: The drug is tested on healthy volunteers
13. Phase 2 of drug development
- ANSWER: trials with people who have the disease for which the drug is
thought to be effective
14. Phase 3 of drug development
- ANSWER: Large numbers of patients in medical research centers receive the
drug in phase 3. This larger sampling provides information about infrequent or rare
adverse effects. The FFA will approve a new drug application if phase 3 studies are
satisfactory.
15. Phase 4 of drug development
- ANSWER: This phase is voluntary and involves post- market surveillance of
the drug's therapeutic effects at the completion of phase 3. The pharmaceutical
company receives reports from doctors and other health care professionals about
the therapeutic results and adverse effects of the drug. Some medications, for
example, have been found to be toxic and have been removed from the market
after their initial release.
16. Explain first pass metabolism
